By Dr. Gavin Magaha PharmD MS – The current turmoil surrounding the 340B Drug Pricing Program and Medicaid Drug Rebate Program. Bloomberg Law, recently reported that pharmaceutical manufacturers and a trade organization have filed at least 23 that extend 340B drug discounts to an unlimited number of contract pharmacies.
Read More
The AMA recently published its new annual analysis of pharmacy benefit manager (PBM) markets confirming low competition among these middlemen in the pharmaceutical supply chain and high vertical integration of PBMs with health insurance companies.
By Tom Dorsett – Drug costs are skyrocketing, but why? First we must understand the cause of high drug costs in order to properly address the problem. For more than twenty-five years, I’ve seen drug costs grow and dominate pharmacy budgets across the United States.
By Tom Dorsett – As of April 2023, the FDA has approved the use of 40 “biosimilars”, which are a less expensive version of an advanced “biologic” medication. The rise of biosimilars is a major source of excitement as a way to control rising drug costs. But is the fervor warranted?
By Tom Dorsett – The U.S. spent nearly $348 billion last year on prescription drugs, the highest in the world and an average of about $1,200 per person. To put this in perspective, Sweden spent about $350 per capita. High drug costs in the U.S. continues to be a threat to patient health and long-term outcomes.